Sai Life

Why is Sai Life Sciences Ltd falling/rising?

As of 11-Jun, the stock price of Sai Life Sciences Ltd is 1,180.30, down 0.72%. Despite today's decline, the stock has strong fundamentals with a year-to-date increase of 30.12% and a one-year increase of 53.31%, indicating robust long-term performance.

As of 11-Jun, the stock price of Sai Life Sciences Ltd is currently at 1,180.30, reflecting a decrease of 8.55 points or 0.72%. Despite this decline, the stock has shown strong performance over various periods, with a year-to-date increase of 30.12% and a one-year increase of 53.31%, significantly outperforming the broader market, which has seen negative returns.<BR><BR>The stock's current drop can be attributed to a few factors. Firstly, it underperformed its sector by 0.32% today, indicating that while the stock has been strong overall, it is facing some short-term challenges. Additionally, there has been a notable decline in investor participation, with delivery volume falling by 12.32% against the five-day average, suggesting reduced trading interest.<BR><BR>However, the stock remains above its moving averages for 5, 20, 50, 100, and 200 days, indicating a generally positive trend in the longer term. The company also boasts a very low debt-to-equity ratio of 0.03 times and has shown impressive growth in operating profit, which has increased at an annual rate of 81.11%. Furthermore, it has consistently declared positive results over the last five quarters, which supports its strong fundamentals.<BR><BR>In summary, while Sai Life Sciences Ltd is experiencing a slight decline in its stock price today, its overall performance remains robust, driven by strong fundamentals and market-beating returns over the past year. The current dip may be a temporary reaction to reduced trading activity rather than a reflection of the company's long-term potential.

Which are the latest news on Sai Life?

What does Sai Life do?

Sai Life Sciences Ltd is a small-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 602 Cr and a net profit of 104 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 71.00 and a market cap of INR 26,212 Cr.

Overview:<BR>Sai Life Sciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited in 1999. The company changed its name to Sai Life Sciences Limited in 2003. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 602 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 104 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 26,212 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 71.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.05 <BR>Return on Equity: 14.29% <BR>Price to Book: 10.54 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Sai Life?

As of 10th June, Sai Life Sciences Ltd has a market capitalization of 26,212.00 Cr, with recent net sales of 2,192.49 Cr and a net profit of 348.92 Cr.

As of 10th June, Sai Life Sciences Ltd has a market capitalization of 26,212.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,192.49 Cr and a Net Profit of 348.92 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,128.35 Cr and Total Assets of 3,145.78 Cr.

Who are the peers of the Sai Life?

Sai Life's peers include Glaxosmi Pharma, J B Chemicals, Emcure Pharma, Wockhardt, Acutaas Chemical, Neuland Labs, Piramal Pharma, Astrazeneca Pharma, and Pfizer. In terms of management risk, growth, and capital structure, Sai Life shows excellent performance compared to its peers, with a 1-year return of 55.07%.

Peers: The peers of Sai Life are Glaxosmi. Pharma, J B Chemicals &, Emcure Pharma, Wockhardt, Acutaas Chemical, Neuland Labs., Piramal Pharma, Astrazeneca Phar, and Pfizer.<BR><BR>Quality Snapshot: Excellent management risk is observed at Glaxosmi. Pharma and Astrazeneca Phar, while Good management risk is found at J B Chemicals &, Emcure Pharma, Acutaas Chemical, Neuland Labs., and Pfizer, and Average management risk is present at Wockhardt and Piramal Pharma. Growth is Excellent at Sai Life and Acutaas Chemical, Good at Emcure Pharma, Neuland Labs., and Pfizer, while Below Average growth is seen at Glaxosmi. Pharma, J B Chemicals &, and Astrazeneca Phar, and Average growth is noted at Wockhardt. Capital Structure is Excellent at Glaxosmi. Pharma, J B Chemicals &, Acutaas Chemical, Neuland Labs., Astrazeneca Phar, and Pfizer, while Good capital structure is found at Emcure Pharma, and Below Average at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.73%, while Glaxosmi. Pharma has the lowest at -36.01%. Sai Life's 1-year return of 55.07% is significantly higher than Glaxosmi. Pharma's return. Additionally, Piramal Pharma and OneSource Speci. have negative six-month returns.

Should I buy, sell or hold Sai Life Sciences Ltd?

Are Sai Life Sciences Ltd latest results good or bad?

Sai Life Sciences Ltd's latest results show record net sales and profit growth, but declining operating margins raise concerns about profitability and competitive positioning. Overall, while revenue and profit increases are positive, margin compression suggests mixed results for investors.

Sai Life Sciences Ltd's latest results present a mixed picture. On one hand, the company achieved a record net sales of ₹602.14 crores in Q4 FY26, reflecting an 8.21% increase quarter-on-quarter and a modest 3.91% year-on-year growth. Additionally, net profit rose to ₹104.24 crores, marking an 18.09% increase year-on-year and a 3.85% rise sequentially.<BR><BR>However, there are concerns regarding profitability. The operating margin, excluding other income, contracted significantly to 29.32% from 33.76% in the previous quarter, indicating pressure on margins. This decline raises questions about the company's pricing power and cost management in a competitive environment. Furthermore, the return on equity at 12.62% is below that of some peers, which may be a concern for investors.<BR><BR>Overall, while the revenue and profit growth are positive indicators, the margin compression and valuation concerns suggest that the results are not entirely favorable. Investors should closely monitor the company's ability to sustain growth and manage margins moving forward.

When is the next results date for Sai Life Sciences Ltd?

The next results date for Sai Life Sciences Ltd is 05 February 2026.

The next results date for Sai Life Sciences Ltd is scheduled for 05 February 2026.

How has been the historical performance of Sai Life?

Sai Life experienced significant financial growth from March 2024 to March 2025, with net sales rising to 1,694.57 Cr and profit after tax increasing to 170.13 Cr. The company improved its operating profit margin to 23.94% and reduced total debt from 710.16 Cr to 128.64 Cr.

Answer:<BR>The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in shareholder's funds and cash reserves, which rose to 463.88 Cr from 158.80 Cr. The company also reduced its total debt significantly from 710.16 Cr to 128.64 Cr. Overall, Sai Life demonstrated robust financial growth and improved profitability in the fiscal year ending March 2025.

Is Sai Life technically bullish or bearish?

As of June 23, 2025, the market trend is neutral with no strong signals, indicating a consolidation phase despite mildly bullish Bollinger Bands.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with no strong bullish or bearish signals present. The MACD and KST indicators show no clear trend on both weekly and monthly time frames. The RSI is also indicating no signal on the weekly and monthly charts. While the Bollinger Bands are mildly bullish on the weekly, the overall lack of definitive trends in the moving averages, Dow Theory, and OBV suggests a consolidation phase. The recent price action, with a decline from the previous close, further supports this neutral outlook.

Is Sai Life overvalued or undervalued?

As of February 7, 2025, Sai Life is considered overvalued with a "very expensive" rating due to high valuation metrics like a PE ratio of 88.33 and an EV to EBITDA of 38.80, significantly exceeding its peers, despite recent stock performance outpacing the Sensex.

As of 7 February 2025, Sai Life has moved from a grade of "does not qualify" to "very expensive." The company is currently overvalued based on its high valuation metrics, including a PE ratio of 88.33, an EV to EBIT of 57.30, and an EV to EBITDA of 38.80. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25 and an EV to EBITDA of 24.91, and Cipla Ltd., which boasts a much lower PE ratio of 22.99 and an EV to EBITDA of 15.93.<BR><BR>In comparison to its industry, Sai Life's valuation appears excessive, particularly when considering its PEG ratio of 0.00, indicating no growth expectations priced into the stock. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 4.16% compared to the Sensex's 1.35%, suggesting some investor optimism despite the high valuation. Overall, given the significant premium over its peers and the valuation grade, Sai Life is deemed overvalued.

Who are the top shareholders of the Sai Life?

The top shareholders of Sai Life include Tpg Asia Vii Sf Pte Ltd with 24.73%, promoter Mytreyi Kanumuri at 10.64%, mutual funds holding 11.54%, and foreign institutional investors at 12.36%, while individual investors own 7.69%. A small portion of promoter holdings is pledged at 2.6741%.

The top shareholders of Sai Life include a mix of institutional and individual investors. The largest public shareholder is Tpg Asia Vii Sf Pte Ltd, holding 24.73%. Among the promoters, Mytreyi Kanumuri, a partner at Marigold Partners, has the highest stake at 10.64%. Additionally, mutual funds hold 11.54% of the shares through 21 schemes, while foreign institutional investors (FIIs) account for 12.36% with 73 FIIs involved. Individual investors collectively hold 7.69% of the company. The majority of the shareholding is held by non-institutional investors, with a small portion of promoter holdings being pledged at 2.6741%.

Has Sai Life declared dividend?

No Dividend History Available